Evidence map›Paper›PMID 41694914›Full record

ArticleCureus2026

Peritoneal Sarcomatosis Secondary to a Gastrointestinal Stromal Tumor Treated With a Multimodal Approach: A Case Report.

Arleyson Daniel Perez Zambrano, Mauricio Garcia Mora, Stefany Rios Acuña

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arleyson Daniel Perez ZambranoSurgical Oncology, Nueva Granada Military University, Bogotá, COL.
Mauricio Garcia MoraSurgical Oncology, National Cancer Institute, Bogotá, COL.
Stefany Rios AcuñaGeneral Surgery, University of La Sabana, Bogotá, COL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 49-year-old woman diagnosed with peritoneal sarcomatosis secondary to an epithelioid gastrointestinal stromal tumor (GIST) (Ki-67 3%, CD117 and DOG1 positive), initially managed with empirical carboplatin-paclitaxel, which was discontinued after histological confirmation. Treatment with imatinib 400 mg/day was initiated, achieving sustained metabolic response and clinical stability. After 12 months of targeted therapy, the patient underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) using mitomycin C. Intraoperative findings revealed extensive peritoneal disease with distal jejunal involvement, achieving CC-1 cytoreduction. The postoperative course was uneventful, and pathology confirmed a metastatic GIST with low mitotic activity. At one-year follow-up, the patient remains clinically stable, with preserved functional status and no evidence of radiological progression. This case illustrates the potential role of a multimodal strategy combining targeted therapy, CRS, and HIPEC in selected patients with peritoneal involvement from GISTs.

Indexed as

cytoreductiongastrointestinal stromal tumorgisthipecimatinibmultimodal treatmentperitoneal sarcomatosis

Identifiers

PMID41694914
PMCPMC12900423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.